Bristol Myers’ TYK2 drug bombs ulcerative colitis test, but hopes are still high with psoriasis filing on deck

Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis, failing to spur clinical remission at three months and missing key secondary endpoints at an interim check-in, the drug giant admitted Thursday.

Details were slim...

Click to view original post